drugset / Trial / NCT02554279

MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population

NCT02554279 ↗

Phase 4 Completed 620 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this trial is to demonstrate non-inferiority of MENOPUR® versus recombinant Follicle Stimulating Hormone (rFSH) (Gonal-f®) with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation (COS) following GnRH treatment.

Timeline

Start
2015-08-31
Primary completion
2017-01-26
Completion
2017-02-02

Outcome

Met primary endpoint

paper OPR/cycle start after fresh transfer was 35.5% with HP-hMG and 30.7% with rFSH (difference: 4.7%, 95% CI -2.7%, 12.1%); noninferiority was established. PMID 32416978 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Menopur Protein / enzyme biologic — —
Comparator recombinant FSH Protein / enzyme biologic — —

Indications